Advanced Thymic Cancer Treated with Carboplatin and Paclitaxel in a Patient Undergoing Hemodialysis

• Miura Satoru

  Department of Medicine (II), Niigata University Medical and Dental Hospital, Japan

• Kagamu Hiroshi

  Department of Medicine (II), Niigata University Medical and Dental Hospital, Japan

• Sakai Takehito

  Department of Internal Medicine, Saiseikai Niigata Daini Hospital, Japan

• Nozaki Koichiro

  Department of Medicine (II), Niigata University Medical and Dental Hospital, Japan

• Asakawa Katsuaki

  Department of Medicine (II), Niigata University Medical and Dental Hospital, Japan

• Moro Hiroshi

  Department of Medicine (II), Niigata University Medical and Dental Hospital, Japan

• Okajima Masaaki

  Department of Medicine (II), Niigata University Medical and Dental Hospital, Japan

• Watanabe Satoshi

  Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Japan

• Yamamoto Suguru

  Department of Medicine (II), Niigata University Medical and Dental Hospital, Japan

• Iino Noriaki

  Department of Medicine (II), Niigata University Medical and Dental Hospital, Japan

• Goto Shin

  Department of Medicine (II), Niigata University Medical and Dental Hospital, Japan

• Kazama Junichiro James

  Department of Medicine (II), Niigata University Medical and Dental Hospital, Japan

• Yoshizawa Hirohisa

  Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Japan

• Narita Ichiei

  Department of Medicine (II), Niigata University Medical and Dental Hospital, Japan

Abstract

A 53-year-old man with an asymptomatic anterior mediastinal tumor undergoing hemodialysis was referred to our institution. He was diagnosed with thymic basaloid carcinoma based on the findings of a chest tomography-guided biopsy and successfully treated with carboplatin (300 mg/m²/day) and paclitaxel (200 mg/m²/day) on day 1 for six three-week cycles. To our knowledge, this is the first report regarding the efficiency of a carboplatin dose-definition method based on the body surface area with paclitaxel in a hemodialysis patient. This report may therefore be useful for treating hemodialysis patients who are candidates for carboplatin and paclitaxel therapy.<br>

Journal

• Internal Medicine

  Internal Medicine 54 (1), 55-58, 2015

  The Japanese Society of Internal Medicine

Keywords

• thymic cancer
• hemodialysis
• carboplatin
• paclitaxel

Details

• CRID: 1390001204874428928
• NII Article ID: 130004902998
• DOI: 10.2169/internalmedicine.54.3484
• ISSN: 13497235
• ISSN: 09182918
• PubMed: 25742894
• Web Site: https://search.jamas.or.jp/link/ui/2015280837
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed